Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
February 06 2024 - 7:30AM
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the
“Company”) (NASDAQ: DYAI), a global biotechnology
company announced it has signed a fully funded evaluation
agreement including commercial option with an undisclosed leading
global biopharmaceutical company to design and produce
recombinant proteins using Dyadic's C1 filamentous fungal based
microbial protein production platform. Under the agreement,
research and development activities will be funded by the
collaborator.
“Dyadic's C1 protein expression platform is
gaining increased traction in research and development targeting
infectious and other diseases,” said CEO Mark Emalfarb, "We
are glad to see the progress of our C1-cell protein production
platform for human and animal biopharmaceuticals and we believe the
recent positive Phase I first in human data for a recombinant
vaccine produced using C1 will spark further interest in the
adoption of Dyadic’s C1 technology.”
Dyadic is committed to enabling its partners and
collaborators in the development of effective preventative and
therapeutic treatments globally. Dyadic is increasing global
outreach to fulfill its mission to make a difference in global
health by building an active pipeline through advancing its
proprietary microbial platform technologies to create needed
products such as recombinant human and bovine albumin and other
biologic vaccines, antibodies, and products.
About Dyadic International,
Inc.
Dyadic International, Inc. is a global
biotechnology company focused on building innovative microbial
platforms to address the growing demand for global protein
bioproduction and unmet clinical needs for effective, affordable,
and accessible biopharmaceutical products and alternative proteins
for human and animal health.
Dyadic’s gene expression and protein production
platforms are based on the highly productive and scalable
fungus Thermothelomyces heterothallica (formerly
Myceliophthora thermophila). Our lead technology, C1-cell
protein production platform, is based on an industrially proven
microorganism (named C1), which is currently used to speed
development, lower production costs, and improve performance of
biologic vaccines and drugs at flexible commercial scales for the
human and animal health markets. Dyadic has also developed the
Dapibus™ filamentous fungal based microbial protein production
platform to enable the rapid development and large-scale
manufacture of low-cost proteins, metabolites, and other biologic
products for use in non-pharmaceutical applications, such as food,
nutrition, and wellness.
With a passion to enable our partners and
collaborators to develop effective preventative and therapeutic
treatments in both developed and emerging countries, Dyadic is
building an active pipeline by advancing its proprietary microbial
platform technologies, including our lead asset DYAI-100 COVID-19
vaccine candidate, as well as other biologic vaccines, antibodies,
and other biological products.
To learn more about Dyadic and our commitment to
helping bring vaccines and other biologic products to market
faster, in greater volumes and at lower cost, please
visit https://www.dyadic.com.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934,
including those regarding Dyadic International’s expectations,
intentions, strategies, and beliefs pertaining to future events or
future financial performance, such as the success of our clinical
trial and interest in our protein production platforms, our
research projects and third-party collaborations, as well as the
availability of necessary funding. Actual events or results may
differ materially from those in the forward-looking statements
because of various important factors, including those described in
the Company’s most recent filings with the SEC. Dyadic assumes no
obligation to update publicly any such forward-looking statements,
whether because of new information, future events or otherwise. For
a more complete description of the risks that could cause our
actual results to differ from our current expectations, please see
the section entitled “Risk Factors” in Dyadic’s annual reports on
Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as
such factors may be updated from time to time in Dyadic’s periodic
filings with the SEC, which are accessible on the SEC’s website and
at www.dyadic.com.
Contact:Dyadic International,
Inc.Ping W. RawsonChief Financial OfficerPhone: (561)
743-8333Email: ir@dyadic.com
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From May 2024 to Jun 2024
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Jun 2023 to Jun 2024